These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 26220866)

  • 1. The NO-modified HIV protease inhibitor as a valuable drug for hematological malignancies: Role of p70S6K.
    Maksimovic-Ivanic D; Mojic M; Bulatovic M; Radojkovic M; Kuzmanovic M; Ristic S; Stosic-Grujicic S; Miljkovic D; Cavalli E; Libra M; Fagone P; McCubrey J; Nicoletti F; Mijatovic S
    Leuk Res; 2015 Oct; 39(10):1088-95. PubMed ID: 26220866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytotoxic and immune-sensitizing properties of nitric oxide-modified Saquinavir in iNOS-positive human melanoma cells.
    Mijatovic S; Maksimovic-Ivanic D; Mojic M; Timotijevic G; Miljkovic D; Mangano K; Donia M; Di Cataldo A; Al-Abed Y; Cheng KF; Stosic-Grujicic S; Nicoletti F
    J Cell Physiol; 2011 Jul; 226(7):1803-12. PubMed ID: 21506111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The new and less toxic protease inhibitor saquinavir-NO maintains anti-HIV-1 properties in vitro indistinguishable from those of the parental compound saquinavir.
    Canducci F; Ceresola ER; Saita D; Al-Abed Y; Garotta G; Clementi M; Nicoletti F
    Antiviral Res; 2011 Sep; 91(3):292-5. PubMed ID: 21763726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic potential of nitric oxide-modified drugs in colon cancer cells.
    Mojic M; Mijatovic S; Maksimovic-Ivanic D; Miljkovic D; Stosic-Grujicic S; Stankovic M; Mangano K; Travali S; Donia M; Fagone P; Zocca MB; Al-Abed Y; McCubrey JA; Nicoletti F
    Mol Pharmacol; 2012 Oct; 82(4):700-10. PubMed ID: 22798453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The antitumor properties of a nontoxic, nitric oxide-modified version of saquinavir are independent of Akt.
    Maksimovic-Ivanic D; Mijatovic S; Miljkovic D; Harhaji-Trajkovic L; Timotijevic G; Mojic M; Dabideen D; Cheng KF; McCubrey JA; Mangano K; Al-Abed Y; Libra M; Garotta G; Stosic-Grujicic S; Nicoletti F
    Mol Cancer Ther; 2009 May; 8(5):1169-78. PubMed ID: 19417156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unique antineoplastic profile of Saquinavir-NO, a novel NO-derivative of the protease inhibitor Saquinavir, on the in vitro and in vivo tumor formation of A375 human melanoma cells.
    Donia M; Mangano K; Fagone P; De Pasquale R; Dinotta F; Coco M; Padron J; Al-Abed Y; Giovanni Lombardo GA; Maksimovic-Ivanic D; Mijatovic S; Zocca MB; Perciavalle V; Stosic-Grujicic S; Nicoletti F
    Oncol Rep; 2012 Aug; 28(2):682-8. PubMed ID: 22665020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ritonavir, nelfinavir, saquinavir and lopinavir induce proteotoxic stress in acute myeloid leukemia cells and sensitize them for proteasome inhibitor treatment at low micromolar drug concentrations.
    Kraus M; Müller-Ide H; Rückrich T; Bader J; Overkleeft H; Driessen C
    Leuk Res; 2014 Mar; 38(3):383-92. PubMed ID: 24418752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Saquinavir-NO-targeted S6 protein mediates sensitivity of androgen-dependent prostate cancer cells to TRAIL.
    Mojic M; Mijatovic S; Maksimovic-Ivanic D; Dinic S; Grdovic N; Miljkovic D; Stosic-Grujicic S; Tumino S; Fagone P; Mangano K; Zocca MB; Al-Abed Y; McCubrey JA; Nicoletti F
    Cell Cycle; 2012 Mar; 11(6):1174-82. PubMed ID: 22370480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro and in vivo anticancer action of Saquinavir-NO, a novel nitric oxide-derivative of the protease inhibitor saquinavir, on hormone resistant prostate cancer cells.
    Donia M; Maksimovic-Ivanic D; Mijatovic S; Mojic M; Miljkovic D; Timotijevic G; Fagone P; Caponnetto S; Al-Abed Y; McCubrey J; Stosic-Grujicic S; Nicoletti F
    Cell Cycle; 2011 Feb; 10(3):492-9. PubMed ID: 21270522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anticancer effects of the nitric oxide-modified saquinavir derivative saquinavir-NO against multidrug-resistant cancer cells.
    Rothweiler F; Michaelis M; Brauer P; Otte J; Weber K; Fehse B; Doerr HW; Wiese M; Kreuter J; Al-Abed Y; Nicoletti F; Cinatl J
    Neoplasia; 2010 Dec; 12(12):1023-30. PubMed ID: 21170266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic antiviral effect of PEG-asparaginase (ONCASPAR), with protease inhibitor alone and in combination with RT inhibitors against HIV-1 infected T-cells: a model of HIV-1-induced T-cell lymphoma.
    Avramis VI; Kwock R; Avramis IA; Cohen LJ; Inderlied C
    In Vivo; 2001; 15(1):1-9. PubMed ID: 11286117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The human immunodeficiency virus (HIV)-1 protease inhibitor saquinavir inhibits proteasome function and causes apoptosis and radiosensitization in non-HIV-associated human cancer cells.
    Pajonk F; Himmelsbach J; Riess K; Sommer A; McBride WH
    Cancer Res; 2002 Sep; 62(18):5230-5. PubMed ID: 12234989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The HIV protease inhibitor saquinavir induces endoplasmic reticulum stress, autophagy, and apoptosis in ovarian cancer cells.
    McLean K; VanDeVen NA; Sorenson DR; Daudi S; Liu JR
    Gynecol Oncol; 2009 Mar; 112(3):623-30. PubMed ID: 19147209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic inhibition of protease-inhibitor-resistant HIV type 1 by saquinavir in combination with atazanavir or lopinavir.
    Dam E; Lebel-Binay S; Rochas S; Thibaut L; Faudon JL; Thomas CM; Essioux L; Hill A; Schutz M; Clavel F
    Antivir Ther; 2007; 12(3):371-80. PubMed ID: 17591027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Saquinavir-NO inhibits IL-6 production in macrophages.
    Momčilović M; Mangano K; Jevtić B; Mammana S; Stošić-Grujičić S; Nicoletti F; Miljković D
    Basic Clin Pharmacol Toxicol; 2014 Dec; 115(6):499-506. PubMed ID: 24842127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of TNF-alpha mediated cell death by HIV-1 specific protease inhibitors.
    Wolf T; Findhammer S; Nolte B; Helm EB; Brodt HR
    Eur J Med Res; 2003 Jan; 8(1):17-24. PubMed ID: 12578750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lovastatin potentiates antitumor effects of saquinavir against human lymphoma cells.
    Issat T; Nowis D; Jakóbisiak M; Golab J
    Oncol Rep; 2004 Dec; 12(6):1371-5. PubMed ID: 15547765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Curcumin stimulates reactive oxygen species production and potentiates apoptosis induction by the antitumor drugs arsenic trioxide and lonidamine in human myeloid leukemia cell lines.
    Sánchez Y; Simón GP; Calviño E; de Blas E; Aller P
    J Pharmacol Exp Ther; 2010 Oct; 335(1):114-23. PubMed ID: 20605902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Important role of caspase-8 for chemosensitivity of ALL cells.
    Ehrhardt H; Wachter F; Maurer M; Stahnke K; Jeremias I
    Clin Cancer Res; 2011 Dec; 17(24):7605-13. PubMed ID: 22010212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-dose 1,25-dihydroxyvitamin D(3) combined with arsenic trioxide synergistically inhibits proliferation of acute myeloid leukemia cells by promoting apoptosis.
    Bae JY; Kim JW; Kim I
    Oncol Rep; 2013 Jul; 30(1):485-91. PubMed ID: 23660868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.